Xeris Biopharma (XERS) officer sells 16,667 shares in Rule 10b5-1 trade

Rhea-AI Filing Summary

Xeris Biopharma Holdings officer Beth Hecht reported an open-market sale of Company stock. She sold 16,667 shares of common stock at a weighted average price of $6.0588 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, she continues to hold 1,176,506 shares directly.

Insights

Equity ownership analyst

Routine 10b5-1 sale of a small portion of existing holdings.

The filing shows officer Beth Hecht sold 16,667 shares of Xeris Biopharma common stock at a weighted average price of $6.0588 per share in an open-market transaction.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a scheduled, programmatic disposition rather than a discretionary trade. Following the sale, she still directly owns 1,176,506 shares, suggesting the transaction represents only a modest portion of her position.

Insider Trade Summary 10b5-1

Net Seller: 16,667 shares ($100,982)

Net Sell 1 txn

Insider Hecht Beth

Role See Remarks

Sold 16,667 shs ($101K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,667	$6.0588	$101K

Holdings After Transaction: Common Stock — 1,176,506 shares (Direct, null)

Footnotes (1)

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.980 to $6.180, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 16,667 shares Weighted average sale price: $6.0588 per share Post-transaction holdings: 1,176,506 shares +1 more

4 metrics

Shares sold 16,667 shares Open-market sale of common stock

Weighted average sale price $6.0588 per share Common stock sale on 2026-06-01

Post-transaction holdings 1,176,506 shares Common stock directly owned after sale

Price range $5.980 to $6.180 Range of sale prices across multiple trades

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"disclosed in the Form 4 insider trading report"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hecht Beth

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		16,667	D	$6.0588(2)	1,176,506	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.980 to $6.180, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Beth Hecht	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Xeris Biopharma (XERS) report for Beth Hecht?

Xeris Biopharma reported that officer Beth Hecht sold 16,667 shares of common stock. The open-market sale was executed at a weighted average price of $6.0588 per share, and it was carried out under a pre-arranged Rule 10b5-1 trading plan.

How many Xeris Biopharma (XERS) shares does Beth Hecht hold after the reported sale?

After the reported transaction, Beth Hecht directly holds 1,176,506 shares of Xeris Biopharma common stock. This figure reflects her position following the open-market sale of 16,667 shares disclosed in the Form 4 insider trading report.

At what prices were Beth Hecht’s Xeris Biopharma (XERS) shares sold?

The reported sale used a weighted average price of $6.0588 per share. According to the filing, individual transactions occurred at prices ranging from $5.980 to $6.180 per share, with full trade-by-trade details available upon request from the issuer or the SEC staff.

Was the Xeris Biopharma (XERS) insider sale by Beth Hecht under a Rule 10b5-1 plan?

Yes, the filing states the transaction was effected under a Rule 10b5-1 trading plan. Such plans are pre-arranged programs that schedule trades in advance, often reducing the significance of trade timing as a signal of insider sentiment.

What type of transaction did Xeris Biopharma (XERS) disclose for Beth Hecht?

The company disclosed an open-market sale of common stock by officer Beth Hecht. The Form 4 identifies the transaction code as “S,” indicating a sale, and describes it as a sale in the open market or a private transaction of 16,667 shares.